Vanda surges on FDA approval of Lilly-partnered motion sickness therapy

On the Move

Comments

(4)

Headquarters of US Food and Drug Administration (FDA) — Grandbrothers/iStock Editorial via Getty Images

Vanda Pharmaceuticals (VNDA) added ~21% in the premarket on Wednesday after the U.S. FDA approved its motion sickness therapy Nereus (tradipitant), developed in partnership with Eli Lilly (LLY).

Accordingly, the neurokinin-1 (NK-1) receptor antagonist will be available in the U.S. as an oral therapy